A promising “two-in-one” experimental drug could tackle both type 2 diabetes and heart disease by slashing cholesterol and ...

Semaglutide reduces cardiovascular events by 23% and direct heart disease death risk by 26% compared to dulaglutide in older adults.

The drug’s effects on cardiovascular and inflammation markers outshined its failure to spur weight loss, analysts wrote.

Regardless of how much weight you lose, GLP-1 drugs like Wegovy and Ozempic could decrease major adverse cardiovascular ...

Semaglutide, the active ingredient in Wegovy and Ozempic, lowers major cardiac event risk, regardless of how much weight a ...

Atorvastatin, one of the world’s most widely prescribed cholesterol-lowering drugs, has played a major role in reducing heart ...

With better access to tools like CCTA and diagnostic tools that leverage CCTA, clinicians can better support their patients in managing overall cardiovascular health, patients will benefit from less ...

Investors have once again turned to Chinese pharmaceutical company Jiangsu Hengrui to create a new biotech startup, this time ...

Generic statins and angiotensin receptor blockers typically used for heart disease also have the potential to bolster the immune systems of patients with Ebola virus and other life-threatening ...

In the treatment of larger narrowed blood vessels, drug-coated balloon catheters have been shown to deliver lasting and ...

People with type 2 diabetes who combined healthy lifestyle habits with GLP-1 receptor agonist (GLP-1 RA) medications had a ...

Researchers at the University of Barcelona found that combining pemafibrate and telmisartan significantly reduces liver fat and cardiovascular risks in MASLD models. The drug duo works better together ...